Jeffrey Michaud, DO
Family Medicine · Lewiston, MENPI 1407885213
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,782 and has fallen 96.1% since, to $69 in 2025. Among family medicine clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$535
- Pfizer$356
- Boehringer Ingelheim$293
- AstraZeneca$203
- Novo Nordisk$170
- AbbVie$158
- plus $796 from 14 others
What the payments were for
- Food & beverage$2,505100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 24 | $535 |
| Pfizer | 40 | $356 |
| Boehringer Ingelheim | 18 | $293 |
| AstraZeneca | 13 | $203 |
| Novo Nordisk | 15 | $170 |
| AbbVie(2 entities) | 7 | $158 |
| Merck | 6 | $152 |
| Sanofi-aventis U.S. LLC | 8 | $148 |
| GSK | 8 | $121 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $78 |
| Novartis | 2 | $46 |
| Indivior Inc. | 2 | $43 |
| EMD Serono, Inc. | 1 | $39 |
| Lilly USA, LLC | 2 | $37 |
| Sanofi Pasteur Inc. | 2 | $28 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Mylan Specialty L.p. | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
How this compares
$2,512 in reported general payments places this provider in the 95th percentile of 466 family medicine providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 96 | $131,536 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 74 | $105,604 |
| OzempicSemaglutide | 53 | $98,391 |
| XareltoRivaroxaban | 63 | $89,371 |
| TrulicityDulaglutide | 49 | $84,444 |
| EliquisApixaban | 56 | $79,435 |
| MounjaroTirzepatide | 26 | $41,508 |
| LinzessLinaclotide | 31 | $28,168 |
| JanuviaSitagliptin Phosphate | 32 | $27,017 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $16,589 |
| MyrbetriqMirabegron | 24 | $16,247 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $11,903 |
| VyvanseLisdexamfetamine Dimesylate | 14 | $7,700 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $7,427 |
| Rosuvastatin Calcium | 215 | $6,978 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $121 | $134,095110 claims |
| Boehringer IngelheimJardiance | $293 | $131,53696 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $37 | $125,95375 claims |
| Novo NordiskOzempic | $170 | $98,39153 claims |
| Johnson & JohnsonXarelto | $17 | $89,37163 claims |
| PfizerEliquis | $356 | $79,43556 claims |
| AbbVieLinzess | $158 | $28,16831 claims |
| MerckJanuvia | $152 | $27,01732 claims |
| Indivior Inc.Suboxone | $43 | $6,10211 claims |
| AstraZenecaFarxiga | $203 | $5,97211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 466 family medicine providers in Maine.
Other family medicine in Lewiston
- Albert HartmanLewiston$33K
- Mina AssadollahzadehLewiston$776
- Kristy Murray-PulsiferSouth Portland$55K
- Brian KnightonFreeport$29K
- Edward YoonPortland$27K
- Jennifer FreeseVeazie$19K
- Kohar der SimonianFalmouth$18K
- Jessica Bloom FosterBangor$14K
- Cecily CannonKennebunk$14K
- Maria AtkinsPortland$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.